Erdinç Nayır

The Silent Impact of Parental Cancer on Children’s Psychosocial Well-Being

Erdinç Nayır, Nilda Ata, Fevziye Toros, Rahime Gökboğa et autres

Ten-year risk of second primary malignancies among chemotherapy-treated early-stage breast cancer survivors: a multicentre cohort study from the Turkish Oncology Group

Haydar Çağatay Yüksel, Elvina Almuradova, Ozge Buyukahiska, Bahiddin Yılmaz et autres

Purpose: As survivorship improves, second primary malignancies (SPMs) have become a clinically relevant late effect of localised breast cancer treatment. Evidence from the Middle East and Balkans is scarce, and contemporary data from Türkiye are lacking. Materials and methods: We conducted a …

tr, us, in, at, kh, Somalie, Afrique du Sud (code pays fourni par la source)

Nutritional Indexes and Their Variations as Predictors of Atezolizumab Plus Chemotherapy Efficacy in Extensive-Stage Small Cell Lung Cancer: A Turkish Oncology Group Study

Nazım Can Demircan, Melek Özdemir, Sevinç Ballı, Naziyet Köse Baytemür et autres

Nutritional status has been associated with prognosis in several cancers. We investigated whether baseline prognostic nutritional index (PNI) and geriatric nutritional risk index (GNRI) as well as their variations during treatment predicted response and survival in extensive-stage small cell lung cancer (ES-SCLC) …

tr (code pays fourni par la source)

The psychosocial status of children who have a parent with cancer.

Erdinç Nayır, Nilda Ata, Fevziye Toros, Aynur Çelik et autres

12083 Background: While numerous studies have investigated the psychosocial status of children affected by childhood cancer, the number of studies investigating this situation in children whose parents have cancer is extremely limited. The purpose of this study is to determine the prevalence …

tr, ca (code pays fourni par la source)

Prognostic impact of hand-foot skin reaction in regorafenib-treated adult-type diffuse gliomas: A multicenter Turkish Oncology Group study

Safa Can Efil, Burak Bi̇lgi̇n, İrem Bilgetekin, Kaan Helvacı et autres

Glioblastoma, IDH-wildtype is the most aggressive primary brain tumor in adults, and treatment options for recurrent disease are limited. Regorafenib, an oral multikinase inhibitor, has shown efficacy in glioblastoma at first recurrence, but its role in later recurrences and in other adult-type …

tr (code pays fourni par la source)

Prognostic Significance of the Combined Albumin-To-Alkaline Phosphatase Ratio (AAPR) and Haemoglobin–Albumin–Lymphocyte–Platelet (HALP) Score in Patients with Metastatic Renal Cell Carcinoma Treated by Targeted Therapy: A New Prognostic Combined Risk Scoring

Tolga Köşeci, Mustafa Seyyar, Mehmet Mutlu Kıdı, Sedat Biter et autres

Background/Objectives: Renal cell carcinoma (RCC) accounts for 2–3% of all cancers, with approximately 25% of patients being detected at the metastatic stage. This study aimed to determine the prognostic significance of co-evaluating two risk parameters: one, the HALP score based on haemoglobin, …

tr, kh (code pays fourni par la source)

The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group ( TOG ) study

Deniz Can Güven, Musa Barış Aykan, Harun Muğlu, Ertuğrul Bayram et autres

INTRODUCTION: The advances in immune checkpoint inhibitors (ICIs) were relatively slow in rare tumors. Therefore, we conducted a multi-center study evaluating the efficacy of ICI monotherapy and the combination of ICIs with chemotherapy (CT) in patients with advanced rare tumors. METHODS: In …

tr (code pays fourni par la source)

Correction: Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

Cengiz Karaçin, Berna Öksüzoğlu, Ayşe Demirci, Merve Keskinkılıç et autres

tr (code pays fourni par la source)

Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

Cengiz Karaçin, Berna Öksüzoğlu, Ayşe Demirci, Merve Keskinkılıç et autres

BACKGROUND: There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which subsequent treatment oncologists prefer in patients with disease progression under CDKi. In …

tr (code pays fourni par la source)

Real-life experience of patients with sarcomatoid renal cell carcinoma: a multicenter retrospective study

Elvina Almuradova, Tuğba Başoğlu, Erdinç Nayır, Ertuğrul Bayram et autres

Sarcomatoid renal cell carcinoma (sRCC) is a rare variant of renal cell carcinoma (RCC) and is associated with a poor prognosis. We reviewed the outcomes of patients from oncology centers in Turkey. Our aim is to share our real-life experience and to …

tr (code pays fourni par la source)

Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer

Cihan Erol, Mehmet Ali Nahit Sendur, İrem Bilgetekin, Duygu Bayir Garbioglu et autres

Aims: The addition of aflibercept to the fluorouracil and irinotecan (FOLFIRI) regimen significantly improved clinical outcomes in patients with metastatic colorectal cancer (CRC) previously treated with oxaliplatin. We aimed to investigate the efficacy and safety of second-line FOLFIRI and aflibercept combination in …

tr (code pays fourni par la source)

The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study

Özlem Özdemir, Baha Zengel, Yaşar Yıldız, Başak Oyan Uluç et autres

In our study, we aimed to evaluate the pathological response rates and side effect profile of adding pertuzumab to the treatment of HER2+ locally advanced, inflammatory, or early-stage breast cancer. This study was conducted by the Turkish Oncology Group (TOG) with data …

tr, co, cy (code pays fourni par la source)